EMA's public statement on the use of thujone-containing products

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1409, 2012-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

EMA recommends restrictions on Multaq use

By  

Reactions Weekly, Vol. 1, Iss. 1371, 2011-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Toxicological and public good considerations for the regulation of nanomaterial-containing medical products

By Faunce Thomas A  

Expert Opinion on Drug Safety, Vol. 7, Iss. 2, 2008-03 ,pp. : 103-106

Informa Healthcare

Access to resources Recommend Favorite

FDA warns against use of products containing aristolochic acid

By  

Inpharma, Vol. 1, Iss. 1285, 2001-01 ,pp. : 20-21

Adis International

Access to resources Recommend Favorite

EMEA issues public statement on leflunomide

By  

Inpharma, Vol. 1, Iss. 1280, 2001-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Health Canada has issued a reminder to consumers advising against the use of products containing aristolochic acid.

By  

Reactions Weekly, Vol. 1, Iss. 1042, 2005-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite